Protocol Ledger

NCT04531475 · Phase II · COMPLETED

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

Interventional Phase II clinical trial protocol NCT04531475 sponsored by Jiangsu Sinorda Biomedicine Co in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-21 Enrollment: 90 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04531475
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04531475
Protocol FieldVerified Registry Value
NCT IdentifierNCT04531475
Consolidated Lead SponsorJiangsu Sinorda Biomedicine Co
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment90 participants (ACTUAL)
Registered Start Date2020-01-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI